AtriCure, Inc. 2006 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2006. AtriCure, Inc. develops, manufactures, and sells the Isolator™ bipolar ablation system, a surgical device used to create lesions in cardiac tissue to treat atrial fibrillation (AF). The company operates as a single reporting segment. While the Isolator clamps are FDA-cleared for soft tissue ablation, substantially all revenue is generated from the off-label use of the system for AF treatment. The company is conducting clinical trials (RESTORE-SR and RESTORE-SR II) to seek FDA approval for AF treatment, with a target PMA filing as early as 2009.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Revenues | $38.2 million | $31.0 million |
| Gross Profit | $30.6 million | $22.9 million |
| Gross Margin | 80.1% | 74.0% |
| Net Loss | $(13.7) million | $(12.7) million |
| Operating Expenses | $45.4 million | $33.8 million |
| Cash and Short-Term Investments | $19.5 million | $33.8 million |
| Working Capital | $23.0 million | $35.9 million |
| Long-Term Debt | $0.7 million | $1.1 million |
Note: All figures are in millions unless otherwise noted. The company had an accumulated deficit of $56.1 million as of December 31, 2006.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 23.5% to $38.2 million, driven primarily by a 26% increase in the volume of disposable units sold. This was partially offset by a decline in worldwide average selling prices due to a higher mix of lower-priced international sales.
- Margin Expansion: Gross margin improved to 80.1% from 74.0%. This was primarily due to a decrease in the average cost per unit following the acquisition of Enable Medical Corporation in 2005, which lowered manufacturing costs.
- Expense Increases: Operating expenses rose significantly to $45.4 million (118.7% of revenue) from $33.8 million. Selling, general, and administrative (SG&A) expenses increased by $8.6 million due to headcount growth and marketing. Research and development (R&D) expenses increased by $3.1 million due to expanded clinical trials and new product development.
- Liquidity: Cash and cash equivalents decreased by approximately $12.5 million, primarily due to the net loss and increased working capital requirements (accounts receivable and inventory).
Guidance, Outlook, and Risks
Outlook and Strategy: Management anticipates that substantially all future revenue will relate to the Isolator system. The company views sole-therapy minimally invasive procedures as its largest growth opportunity. New product introductions include the Isolator Synergy™ clamps (released Q1 2007) and the Cosgrove-Gillinov Left Atrial Appendage Occlusion Clip (FDA filing expected Q2 2007).
Regulatory Risks: The company faces significant risk regarding FDA approval. The Isolator clamps are not FDA-approved for AF treatment. If the FDA requires approval for the company to continue selling the products for their primary use, revenue could cease until approval is obtained. The company is redesigning the RESTORE-SR clinical trial to accelerate enrollment.
Legal and Operational Risks:
- Off-Label Promotion: The company is subject to enforcement actions if deemed to be promoting off-label uses. It received an FDA inspection in 2006 but no formal Form 483 was issued.
- Reimbursement: Changes in Medicare CPT codes effective January 1, 2007, are expected to reduce physician reimbursement for sole-therapy procedures, potentially impacting demand.
- Supply Chain: The company relies on a single supplier (Stellartech) for the Ablation Sensing Unit (ASU), a critical component.
- Litigation: The company is a defendant in a securities class action lawsuit regarding its IPO and has ongoing disputes with a former European distributor (LST B.V.).
Investor Verification Checklist
- FDA Status: Verify the current status of the RESTORE-SR and RESTORE-SR II clinical trials and any new FDA correspondence regarding the off-label use of Isolator clamps.
- Reimbursement Impact: Assess the actual impact of the new 2007 CPT codes on physician reimbursement and subsequent sales volume.
- Cash Burn Rate: Monitor the rate of cash consumption given the $13.7 million net loss and the timeline for potential profitability or additional capital raises.
- Supply Chain Resilience: Confirm the stability of the relationship with Stellartech Research Corporation regarding the supply of ASUs.
- Legal Proceedings: Track the progress of the securities class action lawsuit and the LST B.V. distributor dispute.